ArticleFrontiers in endocrinology2021
Sarcopenia Is Associated With a Risk of Mortality in People With Type 2 Diabetes Mellitus.
Article in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 4 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Factors associated with sarcopenia in elderly patients with type 2 diabetes mellitus.Frontiers in endocrinology · 2026Pooled it
- Sarcopenia in type 2 Diabetes mellitus among Asian populations: prevalence and risk factors based on AWGS- 2019: a systematic review and meta-analysis.BMC endocrine disorders · 2025Pooled it
- Long-term impact of sarcopenia on functional decline and mortality in community-dwelling older adults: a systematic review and meta-analysis.Frontiers in nutrition · 2025Pooled it
- The Effect of Yoga on Health-Related Fitness among Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022Pooled it
- Low-calorie, high-protein diets, regardless of protein source, improve glucose metabolism and cardiometabolic profiles in subjects with prediabetes or type 2 diabetes and overweight or obesity.Diabetes, obesity & metabolism · 2025Trial
- Sarcopenia, an independent predictor for all-cause mortality in rheumatoid arthritis: Insights from the NHANES database.Medicine · 2026Article
- The Concurrent Challenges of Sarcopenia and Frailty: A 5-Year Mortality Risk Evaluation in Geriatric Patients with Type 2 Diabetes Mellitus.Diabetes & metabolism journal · 2026Article
- Sarcopenia and Frailty in Type 2 Diabetes Mellitus: An Overlooked Challenge.Diabetes & metabolism journal · 2026Article
- Prevalence and risk factors of sarcopenic obesity in Thai people with diabetes: A cross-sectional study.Obesity pillars · 2026Article
- Article
- Epigenetic inhibition of class I histone deacetylases by MS-275 attenuates diabetic skeletal muscle atrophy via Akt/ARK5-FoxO and myostatin-Smad signaling.Frontiers in endocrinology · 2026Article
- Sarcopenia in type 2 diabetes mellitus: an imaging review.Frontiers in medicine · 2026Review
- Sarcopenia as a predictor of negative health outcomes in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.Diabetology & metabolic syndrome · 2025Review
- Adenosine Monophosphate-Activated Protein Kinase Activation and Mammalian Target of Rapamycin Complex 1 Inhibition: A Mechanistic Rationale for Anti-Aging Therapy in Type 2 Diabetes.Journal of clinical medicine research · 2025Review
- Skeletal muscle alterations in type 2 diabetes mellitus with and without dyslipidemia.Lipids in health and disease · 2025Article
- Association of possible sarcopenia and its components with all-cause mortality in a middle-aged and older population: a 9-year cohort study.Scientific reports · 2025Article
- Mortality Risk of Sarcopenia and Malnutrition in Older Patients with Type 2 Diabetes Mellitus.Nutrients · 2025Article
- Effects of Blood-Glucose Lowering Therapies on Body Composition and Muscle Outcomes in Type 2 Diabetes: A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- Improved Survival in Malnourished COVID-19 Inpatients with Oral Nutrition Supplementation.Nutrients · 2025Article
- Exercise-Induced Short-Chain Fatty Acids: A Novel Therapeutic Target in Type 2 Diabetes Mellitus with Sarcopenia.Aging and disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcopenia has reportedly been associated with increased risk of mortality in general populations. However, few studies have investigated the association between sarcopenia and mortality in older people with type 2 diabetes mellitus (T2D). This study aimed to investigate the effect of sarcopenia on incident all-cause mortality in older people with T2D. Methods: Low muscle strength were set at handgrip strength <28 kg for men and <18 kg for women, and low skeletal muscle mass index (SMI), evaluated using the impedance body composition analyzer, were set at SMI <7.0 kg/m Results: In this prospective cohort study, 396 people with an average age and duration of diabetes of 71.3 (6.3) years and 16.3 (11.3) years, respectively, were included. Of those included, 14.6% had sarcopenia. During the average 40.5 (16.5) months of follow-up, 13 people (6 out of the 338 without sarcopenia and 7 out of the 58 with sarcopenia) died. Incident rate were 5.1/1000 person years of follow-up in people without sarcopenia and 41.3/1000 person years of follow-up in people with sarcopenia. According to Cox regression analysis, sarcopenia was associated with all-cause mortality (adjusted hazard ratio: 6.12, 95% confidence interval: 1.52-24.7, Conclusion: Sarcopenia is associated with incident all-cause mortality in older outpatients with T2D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.